The team of Takeda (56)established that organoids are containing TGF-βRII mutations incorporating CRISP-Cas9 and found that TGF-βRII mutations could act in conjunction with activin receptor (ACVR) mutations in the TGF-β pathway, resulting in abnormalities in the TGF-β signaling pathway, and verifying that TGF-βR II synergizes with ACVR mutations in colorectal cancer. Here, TGFB1 is linked to colorectal cancer.